Lactitol
FDA-approved product (for solution, oral), marketed as Pizensy.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 0 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Constipation
- Constipation disorder
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Osmotically acting laxatives
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
No supported pathogen reaches ≥40% AI-predicted activity for Lactitol, so it is not among the repurposing candidates. Its predictions are shown below.
AI-predicted activity
AI prediction · nothing measured- MRSA21.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli14.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae21.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis28.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Lactitol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Tubocurarine ChlorideExisting use: Curare alkaloids51.4% AI-predicted activityagainst E. coliNo documented evidence found
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more51.4% AI-predicted activityagainst E. coli50+ registered studies
- BrigatinibExisting use: Neoplasm, Non-small cell lung carcinoma51.2% AI-predicted activityagainst E. coli48 registered studies
- SirolimusExisting use: Adenoma sebaceum, Angiofibroma, Cancer and 5 more51.1% AI-predicted activityagainst E. coli50+ registered studies
- Haloperidol DecanoateExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more51.0% AI-predicted activityagainst E. coli50+ registered studies
- EntrectinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma50.9% AI-predicted activityagainst E. coli46 registered studies
- DasatinibExisting use: Acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 7 more50.8% AI-predicted activityagainst E. coli50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more50.5% AI-predicted activityagainst E. coli35 registered studies
- IvosidenibExisting use: Acute myeloid leukemia, Cholangiocarcinoma50.4% AI-predicted activityagainst E. coli50+ registered studies
- Thiamine HydrochlorideExisting use: Anemia (phenotype), Chronic kidney disease, Encephalopathy and 2 more50.4% AI-predicted activityagainst E. coli50+ registered studies
- VibegronExisting use: Overactive bladder, Polyuria, Urgency urinary incontinence and 1 more50.4% AI-predicted activityagainst E. coli16 registered studies
- Tazemetostat HydrobromideExisting use: Follicular lymphoma, Neoplasm, Sarcoma50.3% AI-predicted activityagainst E. coli3 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Bioequivalence Study of Oxcarbazepine Oral Suspension 300 mg/5mL Under Fed Condition
NCT00951847 · start 2006-10
Registered record
- Registry ID
- NCT00951847
- Conditions
- Healthy
- Interventions
- oxcarbazepine 300 mg/5 mL oral suspension
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2006-10
- Completion
- 2006-12
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionoxcarbazepine 300 mg/5 mL oral suspensionPhaseNot applicableRegistry statusCompletedfMRI and Ghlrein in Obesity and Binge Eating Disorder
NCT02038712 · start 2006-06
Registered record
- Registry ID
- NCT02038712
- Conditions
- Obesity; Binge Eating Disorder
- Interventions
- Fed Condition; Fasted condition; Blood samples; Subjective appetite ratings; fMRI scan
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2006-06
- Completion
- 2013-09
- Enrolment
- 93
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionObesity; Binge Eating DisorderInterventionFed Condition; Fasted condition; Blood samples; Subjective appetite ratings +1 morePhaseNot applicableRegistry statusCompletedBioequivalence Study of 10 mg Amlodipine Besylate/ 20 mg Benazepril Hydrochloride Capsules of Dr.Reddys Laboratories Limited Under Non-fasting (Fed) Conditions
NCT01155908 · start 2005-04
Registered record
- Registry ID
- NCT01155908
- Conditions
- Healthy
- Interventions
- Amlodipine Besylate / Benazepril Hydrochloride
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2005-04
- Completion
- 2005-05
- Enrolment
- 48
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionAmlodipine Besylate / Benazepril HydrochloridePhasePhase 1Registry statusCompletedDexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions
NCT00829673 · start 2004-06
Registered record
- Registry ID
- NCT00829673
- Conditions
- Healthy
- Interventions
- Dexmethylphenidate Hydrochloride; Dexmethylphenidate Hydrochloride
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2004-06
- Completion
- 2004-06
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionDexmethylphenidate Hydrochloride; Dexmethylphenidate HydrochloridePhasePhase 1Registry statusCompletedFed Study of Metoprolol Tartrate Tablets 100 mg and Lopressor® 100 mg
NCT00649116 · start 2002-12
Registered record
- Registry ID
- NCT00649116
- Conditions
- Healthy
- Interventions
- Metoprolol Tartrate Tablets 100 mg; Lopressor® Tablets 100 mg
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2002-12
- Completion
- 2003-01
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionMetoprolol Tartrate Tablets 100 mg; Lopressor® Tablets 100 mgPhasePhase 1Registry statusCompleted